SYRE vs TFX
Spyre Therapeutics, Inc. vs Teleflex Incorporated — AI-powered side-by-side comparison
SYRE
Spyre Therapeutics, Inc.
70
Buy
VS
TFX
Teleflex Incorporated
68
Buy
| Metric | SYRE | TFX |
|---|
| AI Score |
70
|
68
|
| Price |
$103.56
|
$137.00
|
| P/E Ratio |
-52.23×
|
-5.90×
|
| ROE |
-21.7%
|
-29.0%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
0.0%
|
53.8%
|
| Debt / Equity |
0.00×
|
0.99×
|
| Dividend Yield |
0.0%
|
1.0%
|
| RSI (14) |
49.5
|
56.4
|
| Beta |
3.026
|
0.809
|
| Expected Upside |
—
|
+1.7%
|
AI Committee View
Current Innellis committee reasoning for SYRE versus TFX.
SYRE leads by 2 points.
SYRE scores 70/100 (Buy) versus TFX at 68/100 (Buy).
SYRE Committee View
83% agreement
6 analysts
The committee is split. Analysts see this stock differently enough that the current rating reflects genuine uncertainty, not a weak signal.
Bull Case
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Price structure making higher highs and higher lows — Technical
- Trend and market structure agree -- coherent bullish picture — Technical
Bear Case
- ROE of only -24.3% -- cheap may mean cheap for a reason — Value
- MACD histogram negative -- bearish momentum — Technical
TFX Committee View
50% agreement
4 analysts
The committee is split. Analysts see this stock differently enough that the current rating reflects genuine uncertainty, not a weak signal.
Bull Case
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Price structure making higher highs and higher lows — Technical
- VIX regime is low -- calm backdrop supports risk-taking — Macro
Bear Case
- MACD histogram negative -- bearish momentum — Technical
- Daily trend (uptrend) conflicts with the weekly trend (downtrend) -- fighting the larger trend — Technical